Browsing by Author "Sarraju, Ashish"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
    (Elsevier, 2021) Sarraju, Ashish; Li, JingWei; Cannon, Christopher P.; Chang, Tara I.; Agarwal, Rajiv; Bakris, George; Charytan, David M.; de Zeeuw, Dick; Greene, Tom; Heerspink, Hiddo J. L.; Levin, Adeera; Neal, Bruce; Pollock, Carol; Wheeler, David C.; Yavin, Yshai; Zhang, Hong; Zinman, Bernard; Perkovic, Vlado; Jardine, Meg; Mahaffey, Kenneth W.; Medicine, School of Medicine
    We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P < .001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.